ESI is a regenerative medicine company and a leading provider of products and technologies derived from human embryonic stem (hES) cells. ESI is concentrating its therapeutic development on generating cell replacement therapies using frontier technologies and methodology towards the treatment of diabetes and cardiovascular disease. In both cases there is a significant unmet clinical need and considerable commercial opportunity. Currently ESI is developing a robust hES cell technology platform and an extensive intellectual property portfolio, building on established expertise in the area of hES and their directed differentiation. ESI is maintaining a pre-eminent position through the development, protection and dominance of manufacturing processes for hES cells and their progeny. ESI owns six of the twenty-two hES cell lines currently listed on the US National Institutes of Health (NIH) Stem Cell Registry. We can supply hES cells, associated reagents, and comprehensive training to researchers. ESI will progress select applications of any findings, including drug discovery, gene therapy and diagnostics, and therapeutic areas outside its focus, through relationships established with strategic partners.
ESI has adopted the following set of corporate values:
Excellence in all our endeavors, including research, product development, regulatory compliance, shareholder relationships and personnel management, will establish ESI as the world leader in stem cell research.
Social Responsibility to our shareholders, staff and the people we hope to cure, by delivering on the promise of stem cells through leading-edge, highly ethical stem cell research and revolutionary treatments for degenerative diseases.
Integrity through adopting and maintaining the highest ethical standards in research operations, presentations, publications and communications, ensuring that we provide cures which meet both the highest therapeutic and ethical standards.
ESI has a global research program, providing an excellent environment for scientific achievement and career development. ESI is always interested in hearing from highly motivated, talented individuals who feel they would make a valuable contribution to the ESI management or scientific teams. ESI's major in-house therapeutic candidates are Diabetes and Cardiovascular Disease and we are building a research team dedicated to deriving insulin producing islets and cardiomyocytes from human embryonic stem cells.
If you are interested in a career with ESI, send us your CV/resume to:
HR Department
ES Cell International Pte Ltd
11 Biopolis Way
#05-06 Helios
Singapore 138667
Fax: +65 6774 5077
Email us your CV/Resume to employment@escellinternational.com
